Increased eicosanoid levels in the Sugen/chronic hypoxia model of severe pulmonary hypertension

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Al Husseini, Aysar ^a,b   Wijesinghe, Dayanjan S ^c   Farkas, Laszlo ^a   Kraskauskas, Donatas ^a   Drake, Jennifer I ^a   Van Tassel, Ben ^d   Abbate, Antonio ^d   Chalfant, Charles E ^c,d,e,f   Voelkel, Norbert F ^a  

^a Victoria Johnson Research Laboratories   (United States)

^b Department of Internal Medicine Montefiore Mount Vernon Hospital   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; 6 OXOPROSTAGLANDIN F1 ALPHA; ARACHIDONATE 5 LIPOXYGENASE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOPLASMIC PHOSPHOLIPASE A2; DIETHYLCARBAMAZINE; DOCOSAHEXAENOIC ACID; ICOSANOID; ICOSAPENTAENOIC ACID; LEUKOTRIENE C4; LEUKOTRIENE D4; PHOSPHOLIPASE A2; PROSTACYCLIN; PROSTAGLANDIN D2; PROSTAGLANDIN E2; SEMAXANIB; THROMBOXANE B2; UNCLASSIFIED DRUG; 1-((4-METHYLSULFONYL)PHENYL)-3-TRIFLUOROMETHYL-5-(4-FLUOROPHENYL)PYRAZOLE; CYCLOOXYGENASE 2 INHIBITOR; LIPOXYGENASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN F; PROSTAGLANDIN F1; PROSTAGLANDIN F2 ALPHA; PTGS2 PROTEIN, RAT; PYRAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTERIOLE; ARTICLE; CONTROLLED STUDY; DEVELOPMENT; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; ENZYME INHIBITION; HEART RIGHT VENTRICLE HYPERTROPHY; HEART RIGHT VENTRICLE PRESSURE; HISTOPATHOLOGY; HYPOXIA; INFLAMMATION; LUNG DISEASE; LUNG VASCULAR REMODELING; MALE; MUSCULARIZATION; NONHUMAN; PATHOGENESIS; PERIVASCULAR INFLAMMATION; PROTEIN EXPRESSION; PULMONARY ARTERIOLE; PULMONARY HYPERTENSION; RAT; SYSTOLIC BLOOD PRESSURE; TISSUE LEVEL; TREATMENT DURATION; VASCULAR REMODELING; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HEART RIGHT VENTRICLE FUNCTION; HUMAN; HYPERTENSION, PULMONARY; LUNG; METABOLISM; PATHOLOGY; PULMONARY ARTERY; SPRAGUE DAWLEY RAT;

ANIMALIA; RATTUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONATE 5-LIPOXYGENASE; ARTERIOLES; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DIETHYLCARBAMAZINE; DINOPROST; DINOPROSTONE; HUMANS; HYPERTENSION, PULMONARY; HYPOXIA; INFLAMMATION; LEUKOTRIENE D4; LIPOXYGENASE INHIBITORS; LUNG; MALE; PROSTAGLANDINS F; PULMONARY ARTERY; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; THROMBOXANE B2; VENTRICULAR FUNCTION, RIGHT;

EID: 84925686685     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0120157     Document Type: Article

References (48)

1. Kay JM, Gillund TD, Heath D. Mast cells in the lungs of rats fed on Crotalaria spectabilis seeds. Am J Pathol. 1967; 51: 1031-1044. PMID: 4229037
2. Hauge A, Staub N. Prevention of hypoxic vasoconstriction in cat lung by histamine-releasing agent 48/80. J Appl Physiol. 1969; 26: 693-699. PMID: 4182330
3. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992; 327: 70-75. PMID: 1603138
4. Stenmark KR, James SL, Voelkel NF, Toews WH, Reeves JT, Murphy RC. Leukotriene C4 and D4 in neonates with hypoxemia and pulmonary hypertension. N Engl J Med. 1983; 309: 77-80. PMID: 6855869
5. Robbins IM, Kawut SM, Yung D, Reilly MP, Lloyd W, Cunningham G, et al. A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertension. Eur Respir J. 2006; 27: 578-584. PMID: 16507859
6. Kawut SM, Bagiella E, Lederer DJ, Shimbo D, Horn EM, Roberts KE, et al. Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT. Circulation. 2011; 123: 2985-2993. doi: 10.1161/CIRCULATIONAHA.110.015693 PMID: 21593252
7. Barst R (2010) How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension? International Journal of Clinical Practice 64: 23-32.
8. Reeves J, McMurtry I, Voelkel N. Possible role for membrane Lipids in the function of the normal and ab normal pulmonary circulation. Am Rev Respir Dis. 1987; 136: 196-199. PMID: 3300443
9. Voelkel NF, Gerber JG, McMurtry IF, Nies AS, Reeves JT. Release of vasodilator prostaglandin, PGI2, from isolated rat lung during vasoconstriction. Circ Res. 1981; 48: 207-213. PMID: 7006847
10. Walker BR, Voelkel NF, Reeves JT. Pulmonary pressor response after prostaglandin synthesis inhibition in conscious dogs. J Appl Physiol. 1982; 52: 705-709. PMID: 7040323
11. Stenmark KR, Morganroth ML, Remigio LK, Voelkel NF, Murphy RC, Henson PM, et al. Alveolar inflammation and arachidonate metabolism in monocrotaline-induced pulmonary hypertension. Am J Physiol. 1985; 248: H859-866. PMID: 3923843
12. Ono S, Westcott JY, Voelkel NF. PAF antagonists inhibit pulmonary vascular remodeling induced by hypobaric hypoxia in rats. J Appl Physiol. 1992; 73: 1084-1092. PMID: 1400021
13. Voelkel NF, Tuder RM, Wade K, Hoper M, Lepley RA, Goulet JL, et al. Inhibition of 5-lipoxygenase-activating protein (FLAP) reduces pulmonary vascular reactivity and pulmonary hypertension in hypoxic rats. J Clin Invest. 1996; 97: 2491-2498. PMID: 8647941
14. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, Mc Mahon G, Waltenberger J, et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J. 2001; 15: 427-438. PMID: 11156958
15. Abe K, Toba M, Alzoubi A, Ito M, Fagan KA, Cool CD, et al. Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation. 2010; 121: 2747-2754. doi: 10.1161/CIRCULATIONAHA.109.927681 PMID: 20547927
16. Nicolls MR, Mizuno S, Taraseviciene-Stewart L, Farkas L, Drake JI, Al husseini A, et al. New models of pulmonary hypertension based on VEGF receptor blockade-induced endothelial cell apoptosis. Pulm Circ. 2012; 2: 434-442. doi: 10.4103/2045-8932.105031 PMID: 23372927
17. Rai PR, Cool CD, King JA, Stevens T, Burns N, Winn RA, et al. The cancer paradigm of severe pulmonary arterial hypertension. AJRCCM. 2008; 178: 558-564. doi: 10.1164/rccm.200709-1369PP PMID: 18556624
18. Zuo X, Shureiqi I. Eicosanoid profiling in colon cancer: Emergence of a pattern. Prostaglandins Other Lipid Mediat. 2012; 139: 104-105.
19. Dhakal HP, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E, et al. Expression of cyclooxygenase-2 in invasive breast carcinomas and its prognostic impact. Histol Histopathol. 2012; 27: 1315-1325. PMID: 22936450
20. Karavitis J, Hix LM, Shi YH, Schultz RF, Khazaie K, Zhang M, et al. Regulation of COX2 expression in mouse mammary tumor cells controls bone metastasis and PGE2-induction of regulatory T cell migration. PLoS One. 2012; 7: e46342. doi: 10.1371/journal.pone.0046342 PMID: 23029485
21. Obermajer N, Kalinski P. Key role of the positive feedback between PGE(2) and COX2 in the biology of myeloid-derived suppressor cells. Oncoimmunology. 2012; 1: 762-764. PMID: 22934275
22. Van Heumen BW, Roelofs HM, Te Morsche RH, Marian B, Nagengast FM, Peters WH. Celecoxib and tauro-ursodeoxycholic acid co-treatment inhibits cell growth in familial adenomatous polyposis derived LT97 colon adenoma cells. Exp Cell Res. 2012; 318: 819-827. doi: 10.1016/j.yexcr.2012.02.004 PMID: 22366264
23. Oka M, Homma N, Taraseviciene-Stewart L, Morris K, Kraskauskas D, Burns N, et al. Rho Kinase-Mediated Vasoconstriction Is Important in Severe Occlusive Pulmonary Arterial Hypertension in Rats. Circ Res. 2007; 100: 923-929. PMID: 17332430
24. Al Husseini A, Bagnato G, Farkas L, Gomez-Arroyo J, Farkas D, Mizuno S, et al. Thyroid hormone is highly permissive in angioproliferative pulmonary arterial hypertension in rats. Europian Respir J. 2013; 41: 104-114. doi: 10.1183/09031936.00196511 PMID: 22835607
25. Seta F, Rahmani M, Turner P, Funk C. Pulmonary oxidative stress is increased in cyclooxygenase-2 knockdown mice with mild pulmonary hypertension induced by monocrotaline. PLoS One. 2011; 6: e23439. doi: 10.1371/journal.pone.0023439 PMID: 21850273
26. Cathcart MC, Tamosiuniene R, Chen G, Neilan TG, Bradford A, O'byrne KJ, et al. Cyclooxygenase-2-linked attenuation of hypoxia-induced pulmonary hypertension and intravascular thrombosis. J Pharmacol Exp Ther. 2008; 326: 51-58. doi: 10.1124/jpet.107.134221 PMID: 18375790
27. Fredenburgh LE, Liang OD, Macias AA, Polte TR, Liu X, Riascos DF, et al. Absence of cyclooxygenase-2 exacerbates hypoxia-induced pulmonary hypertension and enhances contractility of vascular smooth muscle cells. Circulation. 2008; 117: 2114-2122. doi: 10.1161/CIRCULATIONAHA.107.716241 PMID: 18391113
28. Delannoy E, Courtois A, Freund-Michel V, Leblais V, Marthan R, Muller B. Hypoxia-induced hyperreactivity of pulmonary arteries: role of cyclooxygenase-2, isoprostanes, and thromboxane receptors. Cardiovascular Research. 2010; 85 582-592. doi: 10.1093/cvr/cvp292 PMID: 19710084
29. Janssen LJ. Isoprostanes and lung vascular pathology. Am J Respir Cell Mol Biol. 2008; 39: 3383-3389. doi: 10.1165/rcmb.2008-0117TR PMID: 18441278
30. Maciag A, Sithanandam G, Anderson L. Mutant K-rasV12 increases COX-2, peroxides and DNA damage in lung cells. Carcinogenesis. 2004; 25: 2231-2237. PMID: 15284181
31. Bogaard HJ, Natarajan R, Henderson SC, Long CS, Kraskauskas D, Smithson L, et al. Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation. 2009; 120: 1951-1960. doi: 10.1161/CIRCULATIONAHA.109.883843 PMID: 19884466
32. Bogaard HJ, Mizuno S, Guignabert C, Al Hussaini AA, Farkas D, Ruiter G, et al. Copper dependence of angioproliferation in pulmonary arterial hypertension in rats and humans. Am J Respir Cell Mol Biol. 2012; 46: 582-591. doi: 10.1165/rcmb.2011-0296OC PMID: 22162909
33. Farkas L, Farkas D, Ask K, Möller A, Gauldie J, Margetts P, et al. VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats. J Clin Invest. 2009; 119: 1298-1311. doi: 10.1172/JCI36136 PMID: 19381013
34. Stacher E, Graham BB, Hunt JM, Gandjeva A, Groshong SD, McLaughlin VV, et al. Modern age pathology of pulmonary arterial hypertension. AJRCCM. 2012; 186: 261-272.
35. Tuder RM, Voelkel NF. Pulmonary hypertension and inflammation. J Lab Clin Med. 1998; 132: 16-24. PMID: 9665367
36. Voelkel NF, Gomez-Arroyo J, Abbate A, Bogaard HJ, Nicolls MR. Pathobiology of pulmonary arterial hypertension and right ventricular failure. Eur Respir J. 2012; 40: 1555-1565. doi: 10.1183/09031936.00046612 PMID: 22743666
37. Nicolls MR, Taraseviciene-Stewart L, Rai PR, Badesch DB, Voelkel NF. Autoimmunity and pulmonary hypertension: a perspective. Eur Respir J. 2005; 26: 1110-1118. PMID: 16319344
38. McDonnell T, Westcott J, Czartolomna J, Voelkel N. Role of peptidoleukotrieens in hypoxic pulmonary vasoconstriction in rats. Am J Physiol. 1990; 259: H751-758. PMID: 2118728
39. Tabata T, Ono S, Song C, Noda M, Suzuki S, Tanita T, et al. Role of leukotriene B4 in monocrotaline-induced pulmonary hypertension. Nihon Kyobu Shikkan Gakkai Zasshi. 1997; 35: 160-166. PMID: 9103852
40. Wright L, Tuder RM, Wang J J, Cool CD, Lepley RA, Voelkel NF. 5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension. AJRRCM. 1998; 157: 219-229. PMID: 9445303
41. Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med. 1999; 159: 1925-1932. PMID: 10351941
42. Chida M, Voelkel N. Effects of acute and chronic hypoxia on rat lung cyclooxygenase. Am J Physiol. 1996; 270: L872-878. PMID: 8967523
43. Sagliani KD, Dolnikowski GG, Hill NS, Fanburg BL, Levy BD, Preston IR, et al. Differences between basal lung levels of select eicosanoids in rat and mouse. Pulmonary Circulation. 2013; 3: 82-88. doi: 10.4103/2045-8932.109918 PMID: 23662178
44. Ryan EP, Bushnell TP, Friedman AE, Rahman I, Phipps RP. Cyclooxygenase-2 independent effects of cyclooxygenase-2 inhibitors on oxidative stress and intracellular glutathione content in normal and malignant human B-cells. Cancer Immunology, Immunotherapy. 2008; 57: 347-358. PMID: 17668203
45. Drake JI, Bogaard HJ, Mizuno S, Clifton B, Xie B, Gao Y, et al. Molecular signature of a right heart failure program in chronic severe pulmonary hypertension. Am J Respir Cell Mol Biol. 2011; 45: 1239-1247. doi: 10.1165/rcmb.2010-0412OC PMID: 21719795
46. Chen J, Shearer GC, Chen Q, Healy CL, Beyer AJ, Nareddy VB, et al. Omega-3 fatty acids prevent pressure overload-induced cardiac fibrosis through activation of cyclic GMP/protein kinase G signaling in cardiac fibroblasts. Circulation. 2011; 123: 584-593 doi: 10.1161/CIRCULATIONAHA.110.971853 PMID: 21282499
47. Morganroth ML, Stenmark KR, Morris KG, Murphy RC, Mathias M, Reeves JT, et al. Diethylcarbamazine inhibits acute and chronic hypoxic pulmonary hypertension in awake rats. Am Rev Respir Dis. 1985; 131: 488-492. PMID: 3994144
48. Tian W, Jiang X, Tamosiuniene R, Sung YK, Qian J, Dhillon G, et al. Blocking macrophage leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension. Sci Transl Med. 2013; 5: 200ra117. doi: 10.1126/scitranslmed.3006674 PMID: 23986401